Screener
Ocular Therapeutix OCUL Stock-Based Comp
Stock-Based Comp at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Ocular Therapeutix in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Ocular Therapeutix’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 7:28 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-055256
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Cash flows from operating activities: | ||
| Net loss | $(88,612) | $(64,053) |
| Adjustments to reconcile net loss to net cash used in operating activities | ||
| Stock-based compensation expense | 15,582 | 10,456 |
| Non-cash interest expense | 1,381 | 1,436 |
| Change in fair value of derivative liabilities | (1,455) | 978 |
| Depreciation and amortization expense | 1,283 | 981 |
| Loss on disposal of items of property and equipment | 4,866 | — |
Item 1. Financial Statements (unaudited)
FAQ
- What is Ocular Therapeutix's stock-based comp?
- Ocular Therapeutix (OCUL) reported stock-based comp of $15.58M in Q1 2026.
- How has Ocular Therapeutix's stock-based comp changed year-over-year?
- Ocular Therapeutix's stock-based comp increased by 49.0% year-over-year, from $10.46M to $15.58M.
- What is the long-term trend for Ocular Therapeutix's stock-based comp?
- Over 4 years (2021 to 2025), Ocular Therapeutix's stock-based comp has grown at a 30.3% compound annual growth rate (CAGR), from $14.98M to $43.18M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Ocular Therapeutix's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude